Modafinil's use in combating interferon-induced fatigue

Kari A. Martin, Lois E. Krahn, Vijayan Balan, Marianne J. Rosati

Research output: Contribution to journalArticlepeer-review

22 Scopus citations

Abstract

Interferon (IFN) is an effective agent in the treatment of chronic viral hepatitis C. A variety of adverse neuropsychiatric effects including anxiety, depression, delirium, psychoses, and mania complicates its usage. IFN-α-induced depression is presumed to be composed of two overlapping syndromes: a depression-specific syndrome characterized by depressed mood, anxiety, and cognitive complaints, and a neurovegetative syndrome consisting of fatigue, anorexia, somatic pain complaints, and psychomotor retardation [1]. Our results show that depression-specific symptoms peak at 12 weeks of IFN therapy and respond well to serotoninergic antidepressants [2]. We conclude that neurovegetative symptoms are relatively treatment refractory to antidepressants, occur early in the course of treatment, and tend to persist for the duration of therapy [1].

Original languageEnglish (US)
Pages (from-to)893-896
Number of pages4
JournalDigestive diseases and sciences
Volume52
Issue number4
DOIs
StatePublished - Apr 1 2007

Keywords

  • Chronic hepatitis C
  • Fatigue
  • Interferon
  • Modafinil

ASJC Scopus subject areas

  • Physiology
  • Gastroenterology

Fingerprint Dive into the research topics of 'Modafinil's use in combating interferon-induced fatigue'. Together they form a unique fingerprint.

Cite this